A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.
Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.
Beta-blocker use was linked to an increased risk of heart failure hospitalizations in a recent study of patients with “stiff heart” HF—a concerning finding considering the majority of such patients take the drugs as part of their care regimen.
Novoheart, a Vancouver-based stem cell biotech company, is pairing with biopharmaceutical giant AstraZeneca to develop the world’s first human-specific in vitro functional model of heart failure with preserved ejection fraction.
Brushing teeth three or more times a day could dramatically lower a person’s risk for CVDs like heart failure and atrial fibrillation, according to preliminary research out of Ewha Womans University in Seoul, South Korea.
Patients with heart failure and reduced ejection fraction are well served by treatment with the glucose-lowering drug dapagliflozin, as it warded off death and hospitalization while also improving quality of life when added to standard care regimens in a major trial.
Results from the world’s largest comprehensive study of hypertrophic cardiomyopathy patients are in—and they’re providing cardiologists with a wealth of previously unknown information about the disease.